Clinical Trials Directory

Trials / Completed

CompletedNCT01941966

A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.

A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
51 (estimated)
Sponsor
Instituto do Cancer do Estado de São Paulo · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The squamous cell carcinoma (SCC) of the anal canal is an uncommon neoplasia which corresponds to 1-5% of intestinal tumors. However the risk of SCC of the anal canal has been growing recently. The standard treatment of anal cancer stage II-III is multimodal and consists of combined chemotherapy (infusional 5-fluorouracil and mitomycin) and radiotherapy. This scheme currently used was proposed in 1974, and since then no other effective treatment has been developed. The purpose of this study is to determine the efficacy and toxicity of the combination of capecitabine and mitomycin with radiotherapy in patients with carcinoma of the anal canal. For this will be selected 51 patients to be treated with chemo-radiotherapy. The primary endpoint will be local control rate after 6 months of the end of radiotherapy and chemotherapy, defined by the rate of radiological and clinical neoplasia.

Conditions

Interventions

TypeNameDescription
DRUGCapecitabineCapecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
DRUGMitomycins15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
RADIATIONRadiotherapyDose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks

Timeline

Start date
2010-11-01
Primary completion
2013-11-01
First posted
2013-09-13
Last updated
2014-03-28

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT01941966. Inclusion in this directory is not an endorsement.